ADMA Biologics, Inc.
NASDAQ:ADMA
Overview | Financials
Company Name | ADMA Biologics, Inc. |
Symbol | ADMA |
Currency | USD |
Price | 17.4 |
Market Cap | 4,113,186,000 |
Dividend Yield | 0% |
52-week-range | 4.16 - 23.64 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Adam S. Grossman |
Website | https://www.admabiologics.com |
An error occurred while fetching data.
About ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD